Arrowhead Pharmaceuticals Inc - Pursuant to 2022 Agreement With Royalty Pharma Arrowhead Is Further Eligible to Receive $110 Mln From Royalty Pharma
Arrowhead Pharmicals Inc——根据2022年与Royalty Pharma签订的协议,Arrowhead还有资格从Royalty Pharma获得1.1亿美元
Arrowhead Pharmaceuticals Inc - Pursuant to 2022 Agreement With Royalty Pharma Arrowhead Is Further Eligible to Receive $110 Mln From Royalty Pharma
Arrowhead Pharmicals Inc——根据2022年与Royalty Pharma签订的协议,Arrowhead还有资格从Royalty Pharma获得1.1亿美元
使用浏览器的分享功能,分享给你的好友吧